Overview
Retatrutide is an investigational 'triple agonist' targeting the GLP-1, GIP, and glucagon receptors. It is still in clinical development and has generated significant interest from early weight-management trial results.
How It's Thought to Work
Simultaneous activity at three metabolic hormone receptors is being studied for effects on appetite, energy expenditure, and glucose control.
What the Research Says
Phase 2 human trial results have been published; larger Phase 3 trials are ongoing. It is not yet approved.
Regulatory & Legal Status
Investigational — not FDA-approved. Any product sold to consumers as 'retatrutide' is unapproved and unregulated.
Safety Considerations
Long-term human safety is still being established in trials. Not available as an approved medicine. Consult a clinician.